Evidence map›Paper›PMID 42362306›Full record

ReviewThe Urologic clinics of North America2026

Economic Considerations in the Management of Superficial Bladder Cancer.

Veerain K Gupta, Daniel D Joyce, Kevin M Wymer, Vidit Sharma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Urologic clinics of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Veerain K GuptaDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Daniel D JoyceDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Kevin M WymerDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Vidit SharmaDepartment of Urology, Mayo Clinic, Rochester, MN, USA. Electronic address: Sharma.Vidit@mayo.edu.

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
NCI NIH HHS K12 CA090625
6 · The paper itself

Abstract

Non-muscle invasive bladder cancer represents the majority of bladder cancer cases and imposes a significant economic burden due to high recurrence rates and intensive surveillance. Cost-effectiveness analyses help compare treatment strategies, but integration into clinical guidelines remains limited. Financial toxicity affects many patients, particularly those with lower income. While novel therapies and diagnostic tools show promise, their cost-effectiveness is variable. Future efforts should focus on incorporating cost-utility data into guidelines and addressing both direct and indirect costs to optimize care and reduce financial strain for patients and health care systems.

Indexed as

Health Care CostsNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsCost-Benefit AnalysisCost-Effectiveness AnalysisCost of IllnessHumansCost-effectiveness analysisEconomic burdenFinancial toxicityNon–Muscle-Invasive Bladder Cancer

Identifiers

PMID42362306
PMCPMC13572986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.